Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).
Search results for
"Targeted Agents"
-
-
Apparatus
Acs Med. Chem. Lett.| Protac-Targeted Jak2 Protein Kinase: a New Approach To Cancer Therapy
A new approach to cancer treatment!